Jump to content

KZA - KAZIA THERAPEUTICS LIMITED


colaiscute

Recommended Posts

  • Replies 4.4k
  • Created
  • Last Reply

Top Posters In This Topic

I really like this stock as a bio spec. It is volatile because of low volume trading but thats part of the reason I find it exciting. Most of my stock don't change tooooooo much day to day but this one keeps me on my toes. If even some of the the trials come off I will be happy.

 

Link to comment
Share on other sites

With the patent granted for Phenx. the stock should sit comfortably above $7 whilst we wait for phase II trials to be complete and phase II to start. Of course if Phase II proves conclusive enough the FDA may in fact fastrack the drug through phase III.

 

Whilst there is a long way to go still, I think we could be looking at a stock well into the $30 mark by mid next year.

Link to comment
Share on other sites

Novogen gets patent for anti-cancer drug

November 19, 2003 - 12:05PM

 

Print this article

Email to a friend

 

 

 

Pharmaceutical company Novogen said it secured the US patent covering methods for treating all cancers with the anti-cancer drug phenoxodial, which is undergoing human clinical trials in Australia.

 

This includes ovarian, breast, prostate and cervical cancers.

 

Phenoxodiol is in phase two human trials in the US and Australia, with the rights to commercialise the drug licensed to the Novogen majority owned US company US Marshall Edwards.

 

Novogen managing director Christopher Naughton said the latest US patent joined a suite of existing protection which consolidated and further secured Novogen's intellectual property position.

 

He said the company managed its international research and development programs using the experience and clinical research capabilities of universities and hospitals in Australia, the US and other key international locations.

 

Shares in Novogen rose 26 cents, or 3.9 per cent, to $6.95.

Link to comment
Share on other sites

Novogen diagnosis looks good

Nov 26 Martin Pretty

 

The loyal investors who prop up the share registry of drug developer Novogen have much to be pleased about. Over the past week, Novogen shares rose 6per cent after being granted a new patent and a listing of a subsidiary in the United States.

 

Shareholders would have been all grins at the company's annual general meeting when chairman Philip Johnston pointed out their stock was the best-performing component of the S&P/ASX 200 Index during the 2002-03 financial year.

 

Then again, with more than 50per cent of Novogen shares held by US investors, the majority would not have attended the Sydney meeting.

 

Last week, Novogen shares were given an additional push when the company said it had been granted a US patent that covered methods for treating all benign and malignant cancers with its drug Phenoxodial.

 

Phenoxodial is in phase II clinical trials in Australia and the US, with results expected early in calendar 2004. Development responsibilities and commercialisation rights lie with a Novogen subsidiary, Marshall Edwards, which was floated on London's Alternative Investment Market after the Australian Securities and Investments Commission stopped a planned IPO in Australia.

 

Novogen's 95.1per cent share of Marshall Edwards is valued at about $660million by the market. It listed on AIM as a stapled security, with a warrant attached to each share. The warrants expire on November 30 and are in the money. This means Marshall Edwards stands to gain $US10million ($14million) in coming days. It is ÃÆâ€â„¢ÃƒÆ’ƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚£ also raising up to $US13million by an issue of new stapled securities for a Nasdaq listing.

 

Novogen managing director Christopher Naughton says he hopes that Marshall Edwards' Nasdaq listing will be completed before the year's end.

 

Novogen has been compared by some to another ASX-listed cancer drug developer, Progen Industries.

 

Like Novogen, Progen enjoys the renewed appetite for risk by retail investors. Its share price has risen 80per cent over the past 12 months. It has concluded the first phase II trial of its PI-88 compound. However, some analysts say that Progen is now in more advanced clinical trials.

 

Prospects for Progen's PI-88 were boosted by the success that US biotech giant Genentech has had with a late-stage clinical trial of its new drug Avastin. The trial has proved the usefulness of drugs designed to restrict tumour growth by inhibiting angiogenesis (the growth of new blood vessels) and thus blocking the tumour's blood supply.

 

Avastin achieves this by blocking a known angiogenic growth factor VEGF. Progen's PI-88 blocks the action of VEGF and other angiogenic factors, FGF-1 and FGF-2, as well as inhibiting an enzyme called heparanase, which liberates angiogenic growth factors stored in blood-vessel walls.

 

The market capitalisation of Progen is only $50 million compared with Novogen's $720 million.

 

Novogen also has offshore institutional support - the $US820million Oppenheimer International Growth portfolio has a 14per cent stake in Novogen and holds an interest in Marshall Edwards.

 

Novogen also has a larger product pipeline.

But Novogen and Progen have different strategies.

 

Progen is chasing a partnering or licensing deal with a major drug company for the late-stage development of PI-88.

 

By contrast, Novogen is focused on going it alone and using subsidiary Marshall Edwards to market its products.

 

eG Capital analyst Alison Coutts estimates that there are more than 150 different anti-angiogenesis agents in development, with about 30 in clinical trials. All act on inhibiting blood-vessel growth via several different mechanisms affecting enzymes, receptors, growth factors and hormones.

 

Novogen's Phenoxodiol tackles cancer in a different way.

The drug is being developed to inhibit two key targets on cancer cells that are critical to the growth and survival of most forms of cancer.

 

One target is a growth receptor known as tNOX. The other is a protein known as sphingosine kinase.

Novogen may have plans to float another subsidiary, Glycotex, which was established in the US to provide a commercial vehicle for Novogen's glucan technology.

"It's a potential development we could consider in due course," Novogen's Naughton says.

 

During April 2003, Glycotex raised $500,000 in a private placement from Australian and international investors. Novogen now owns 97.6per cent of Glycotex, giving the subsidiary a theoretical market capitalisation of $21million.

 

 

Link to comment
Share on other sites

  • 3 weeks later...
  • 1 month later...

North American Menopause Society Statement Cites Dietary Isoflavones As Acceptable Treatment Option for Menopause

 

Friday January 16, 12:23 pm ET

 

Novogen Launches Center for Isoflavone Research

 

 

STAMFORD, Conn., Jan. 16 /PRNewswire/ -- Novogen Ltd. announced today the launch of the Novogen Center for Isoflavone Research (NCIR), which seeks to provide information to the media and consumers interested in the latest available research on isoflavone consumption and related health implications.

The Center's creation comes in response to the need to meet the growing interest in research supporting the use of dietary isoflavones as a natural alternative in the treatment of many ailments associated with the aging process such as menopausal symptoms in women and Benign Prostatic Hyperplasia (BPH), or enlarged prostate, in men.

 

"NCIR serves as a one-stop clearinghouse for background information on the latest in isoflavone research," said Aaron Stryker, executive director of the Center. "Researchers believe that isoflavones may hold answers to medical questions surrounding illnesses associated with aging such as cancer, menopause, and prostate complications. The Center will help to draw attention to the growing body of science supporting isoflavones."

 

In conjunction with its launch, NCIR has released a media kit (link to electronic files is at http://info.novogen.com/cfir/mediakit.php) of isoflavone research materials supplementing the North American Menopause Society's (NAMS) position statement on the treatment of menopause symptoms released today. This comprehensive review of the science behind all major options for women suffering from menopausal symptoms concludes that supplementing behavior change with dietary isoflavones is an acceptable treatment option.

 

The Novogen Center for Isoflavone Research is distributing this electronic media kit ahead of its anticipated schedule, because the media materials may be of immediate use to those interested in the NAMS statement and its implication for menopausal women.

 

The media kit is the first of what the Center plans to be a periodic update of the information available on the research of dietary isoflavones. It offers information on the guidelines highlighted in the NAMS position statement (as well as direct access to the statement itself), the research surrounding dietary isoflavones and opportunities to speak with experts in the field. The kit also includes recommended isoflavone intake levels along with a table of methods for reaching those levels. The kit is available with this release for view electronically or can otherwise be obtained by request from any of the media contacts provided.

 

Based in Sydney, Australia, Novogen is the world leader in isoflavone research. The company manages its international research and development program using the expertise and clinical research capabilities of universities and hospitals in the U.S., Australia and other key international locations. The company's lead anti-cancer compound phenoxodiol, which is based on an isoflavone-related molecule, is in several human clinical trials around the world.

 

CONTACT: Aaron Stryker of Novogen Center for Isoflavone Research, +1-203-327-1188 ext. 16, or David Sheon, +1-202-518-6321, for Novogen Center for Isoflavone Research.

 

 

 

 

--------------------------------------------------------------------------------

Source: Novogen Center for Isoflavone Research

Link to comment
Share on other sites

IN REPLY TO A POST BY theadder, Sat 17/01/04 09:55am   [READ POST]

North American Menopause Society Statement Cites Dietary Isoflavones As Acceptable Treatment Option for Menopause

Friday January 16, 12:23 pm ET

Novogen Launches Center for Isoflavone Research


STAMFORD, Conn., Jan. 16 /PRNewswire/ -- Novogen Ltd. announced today the launch of the Novogen Center for Isoflavone Research (NCIR), which seeks to provide information to the media and consumers interested in the latest available research on isoflavone consumption and related health implications.
The Center's creation comes in response to the need to meet the growing interest in research supporting the use of dietary isoflavones as a natural alternative in the treatment of many ailments associated with the aging process such as menopausal symptoms in women and Benign Prostatic Hyperplasia (BPH), or enlarged prostate, in men.

"NCIR serves as a one-stop clearinghouse for background information on the latest in isoflavone research," said Aaron Stryker, executive director of the Center. "Researchers believe that isoflavones may hold answers to medical questions surrounding illnesses associated with aging such as cancer, menopause, and prostate complications. The Center will help to draw attention to the growing body of science supporting isoflavones."

In conjunction with its launch, NCIR has released a media kit (link to electronic files is at http://info.novogen.com/cfir/mediakit.php) of isoflavone research materials supplementing the North American Menopause Society's (NAMS) position statement on the treatment of menopause symptoms released today. This comprehensive review of the science behind all major options for women suffering from menopausal symptoms concludes that supplementing behavior change with dietary isoflavones is an acceptable treatment option.

The Novogen Center for Isoflavone Research is distributing this electronic media kit ahead of its anticipated schedule, because the media materials may be of immediate use to those interested in the NAMS statement and its implication for menopausal women.

The media kit is the first of what the Center plans to be a periodic update of the information available on the research of dietary isoflavones. It offers information on the guidelines highlighted in the NAMS position statement (as well as direct access to the statement itself), the research surrounding dietary isoflavones and opportunities to speak with experts in the field. The kit also includes recommended isoflavone intake levels along with a table of methods for reaching those levels. The kit is available with this release for view electronically or can otherwise be obtained by request from any of the media contacts provided.

Based in Sydney, Australia, Novogen is the world leader in isoflavone research. The company manages its international research and development program using the expertise and clinical research capabilities of universities and hospitals in the U.S., Australia and other key international locations. The company's lead anti-cancer compound phenoxodiol, which is based on an isoflavone-related molecule, is in several human clinical trials around the world.

CONTACT: Aaron Stryker of Novogen Center for Isoflavone Research, +1-203-327-1188 ext. 16, or David Sheon, +1-202-518-6321, for Novogen Center for Isoflavone Research.




--------------------------------------------------------------------------------
Source: Novogen Center for Isoflavone Research

Thank,s for the post ADDER as usual your info is great, http://www.asxboard.com/html/emoticons/graduated.gif

Cheers /Moosey

Link to comment
Share on other sites

IN REPLY TO A POST BY theadder, Sat 17/01/04 09:55am   [READ POST]

North American Menopause Society Statement Cites Dietary Isoflavones As Acceptable Treatment Option for Menopause

Friday January 16, 12:23 pm ET

Novogen Launches Center for Isoflavone Research


STAMFORD, Conn., Jan. 16 /PRNewswire/ -- Novogen Ltd. announced today the launch of the Novogen Center for Isoflavone Research (NCIR), which seeks to provide information to the media and consumers interested in the latest available research on isoflavone consumption and related health implications.
The Center's creation comes in response to the need to meet the growing interest in research supporting the use of dietary isoflavones as a natural alternative in the treatment of many ailments associated with the aging process such as menopausal symptoms in women and Benign Prostatic Hyperplasia (BPH), or enlarged prostate, in men.

"NCIR serves as a one-stop clearinghouse for background information on the latest in isoflavone research," said Aaron Stryker, executive director of the Center. "Researchers believe that isoflavones may hold answers to medical questions surrounding illnesses associated with aging such as cancer, menopause, and prostate complications. The Center will help to draw attention to the growing body of science supporting isoflavones."

In conjunction with its launch, NCIR has released a media kit (link to electronic files is at http://info.novogen.com/cfir/mediakit.php) of isoflavone research materials supplementing the North American Menopause Society's (NAMS) position statement on the treatment of menopause symptoms released today. This comprehensive review of the science behind all major options for women suffering from menopausal symptoms concludes that supplementing behavior change with dietary isoflavones is an acceptable treatment option.

The Novogen Center for Isoflavone Research is distributing this electronic media kit ahead of its anticipated schedule, because the media materials may be of immediate use to those interested in the NAMS statement and its implication for menopausal women.

The media kit is the first of what the Center plans to be a periodic update of the information available on the research of dietary isoflavones. It offers information on the guidelines highlighted in the NAMS position statement (as well as direct access to the statement itself), the research surrounding dietary isoflavones and opportunities to speak with experts in the field. The kit also includes recommended isoflavone intake levels along with a table of methods for reaching those levels. The kit is available with this release for view electronically or can otherwise be obtained by request from any of the media contacts provided.

Based in Sydney, Australia, Novogen is the world leader in isoflavone research. The company manages its international research and development program using the expertise and clinical research capabilities of universities and hospitals in the U.S., Australia and other key international locations. The company's lead anti-cancer compound phenoxodiol, which is based on an isoflavone-related molecule, is in several human clinical trials around the world.

CONTACT: Aaron Stryker of Novogen Center for Isoflavone Research, +1-203-327-1188 ext. 16, or David Sheon, +1-202-518-6321, for Novogen Center for Isoflavone Research.




--------------------------------------------------------------------------------
Source: Novogen Center for Isoflavone Research

Hi again Adder just a question as you are THE patents MAN,how can I find out more on an Australian patent 2003905271 dated 26-9-03 it about a company called DCR Global and the patent is about a Transmitter. I don't know if you can help but if you can it would be much appreciated

Cheers/moosey

Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now

×
×
  • Create New...